advertisement

---

Tabuchi H 10

Showing records 1 to 10 | Display all abstracts from Tabuchi H

60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Shimizu Y
Clinical Ophthalmology 2015; 9: 475-482

---

60232 Prostaglandin-associated periorbitopathy in latanoprost users
Nakakura S
Clinical Ophthalmology 2015; 9: 51-56

---

60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Nakakura S
Clinical Ophthalmology 2015; 9: 475-482

---

60232 Prostaglandin-associated periorbitopathy in latanoprost users
Yamamoto M
Clinical Ophthalmology 2015; 9: 51-56

---

60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Nishiyama M
Clinical Ophthalmology 2015; 9: 475-482

---

60232 Prostaglandin-associated periorbitopathy in latanoprost users
Terao E; Nagatomi N
Clinical Ophthalmology 2015; 9: 51-56

---

60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Tabuchi H
Clinical Ophthalmology 2015; 9: 475-482

---

60232 Prostaglandin-associated periorbitopathy in latanoprost users
Matsuo N
Clinical Ophthalmology 2015; 9: 51-56

---

60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Kiuchi Y
Clinical Ophthalmology 2015; 9: 475-482

---

60232 Prostaglandin-associated periorbitopathy in latanoprost users
Fujisawa Y; Fujio Y; Tabuchi H; Kiuchi Y
Clinical Ophthalmology 2015; 9: 51-56

---